about
Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 InhibitionComprehensive characterization of the Published Kinase Inhibitor SetProfile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assaysStructure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoniNew compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS)High-throughput manual parallel synthesis using SynPhase crowns and lanterns.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Kinase-targeted library design through the application of the PharmPrint methodology.Enhancements of screening collections to address areas of unmet medical need: an industry perspective.A rapid three-component MgI(2)-mediated synthesis of 3,3-pyrollidinyl spirooxindoles.Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth.Plasmodium kinases as targets for new-generation antimalarials.Progress towards a public chemogenomic set for protein kinases and a call for contributions.Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.Discovery of thiophene inhibitors of polo-like kinase.2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor.A public-private partnership to unlock the untargeted kinome.Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.New tools for carbohydrate sulfation analysis: heparan sulfate 2--sulfotransferase (HS2ST) is a target for small-molecule protein kinase inhibitorsNew tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitorsCovalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in ChordomaArray synthesis of progesterone receptor antagonists: 3-aryl-1,2-diazepinesChemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cellsIn depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinasesBinding and structural analyses of potent inhibitors of the human Ca2+/calmodulin dependent protein kinase kinase 2 (CAMKK2) identified from a collection of commercially-available kinase inhibitorsSGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancerIn Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory ScaffoldsCDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse modelQuantifying CDK inhibitor selectivity in live cells
P50
Q27700161-FF937619-5283-4D65-A71D-898CB3F41BBFQ27702518-3F98B75B-B58C-4207-80A0-3CD5879345F0Q28487785-559E7DC5-57BC-45C9-AC15-9E2679FE18E9Q28552326-81101BB0-4E20-43F9-AABD-911DB13AA973Q30417002-613210C5-A758-4B41-8D76-93FA1AEE2BA0Q30486521-00E17B44-B91E-439E-B4CD-C62CA6E1FFC0Q31134504-F7C07163-5EA8-40AC-B213-330BCD897889Q33276007-C12BDF75-8B36-4894-9355-1416159B6215Q33389288-DE7CB9C2-E68E-4CBF-80D0-BAE923D44F0AQ33562562-FD681CDB-60B5-426D-B42D-1C7B8DD343EBQ33678178-A6402568-DC2A-41A9-A955-52AFE7112704Q36986274-9BCA0BB9-AF54-4EB9-98ED-F7BCA44A23A5Q38066993-794486B0-F939-4341-9D1C-42BE30C0BE14Q38646648-0D7EC82D-AC6C-4F69-AE80-0539C6A94EB5Q38668661-A8E1D019-D0D0-4275-817E-11D49C192E3FQ39903318-60A5C477-70DA-455C-A2FD-DA9430211E32Q43679872-0ABB6DE2-57F7-4A42-8AEE-3BD9443F9395Q44090999-90E230B3-8741-4831-9420-E16DC83EF65CQ46227082-0A31FF80-CEF0-4E64-94C7-6B1094D4FDDEQ56833662-9BAAFBB4-BC0C-4F91-8AB2-897EACEF7238Q56994432-9572B9F4-D74B-41A2-A83A-A64F40C852DAQ60193666-31BEFA01-F2EC-407C-BEAF-E246364B04AEQ64039562-78258640-DAB5-44B5-A7E1-7AF7561C1EC0Q83295806-A10FB148-A1EA-459B-8A5B-B5DA67EEF700Q90441063-7F1048AA-4181-44E5-BA6E-97A2F0823DF9Q90950369-CC66D5AB-A1AF-4EDB-8B0E-1F2AE378522DQ91235324-C756D68D-5721-4421-92F0-06C1E0AD57A5Q91616902-4E82089D-1C4D-498B-B5E4-FA546D8F83E5Q92525406-1E9379D7-833C-461A-B56C-3FCDC94F147DQ92663930-5AC862FD-8CB3-4D23-B05E-139FF0A2B7AAQ94461416-96F3B889-1999-45BC-A40E-DB0258999761Q96127369-5F25119C-D451-410B-BA41-7B6DE457F1DB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David Drewry
@ast
David Drewry
@en
David Drewry
@es
David Drewry
@nl
David Drewry
@sl
type
label
David Drewry
@ast
David Drewry
@en
David Drewry
@es
David Drewry
@nl
David Drewry
@sl
prefLabel
David Drewry
@ast
David Drewry
@en
David Drewry
@es
David Drewry
@nl
David Drewry
@sl
P106
P21
P31
P496
0000-0001-5973-5798